Description_x000D_ Application_x000D_ Orlistat has been used as an inhibitor:_x000D_ • of fatty acid synthase in long-term estrogen-deprived (LTED) variant cell lines_x000D_ • of lipase in screening lipase inhibition by raspberry extract_x000D_ • in in vitro pancreatic lipase activity assay_x000D_ Packaging_x000D_ 25, 100 mg in glass bottle_x000D_ Biochem/physiol Actions_x000D_ Orlistat impairs intestinal fat absorption and is effective in weight management. It is regarded as a safe drug for treating obesity. It delays the progression of type 2 diabetes mellitus especially in obese and improves glycemic parameters. Long term usage of orlistat results in improved weight reduction and it may not contribute in colorectal carcinogenesis._x000D_ Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase._x000D_ Features and Benefits_x000D_ This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here._x000D_ Other Notes_x000D_ Solution is not completely clear, small particles may remain floating.